Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Aug 1;7(8):1178-1185.
doi: 10.1001/jamaoncol.2021.1910.

Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non-Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy: The Phase 3 PORT-C Randomized Clinical Trial

Zhouguang Hui  1 , Yu Men  1 , Chen Hu  2 , Jingjing Kang  3   4 , Xin Sun  3 , Nan Bi  3 , Zongmei Zhou  3 , Jun Liang  3 , Jima Lv  3 , Qinfu Feng  3 , Zefen Xiao  3 , Dongfu Chen  3 , Yan Wang  5 , Junling Li  5 , Jie Wang  5 , Shugeng Gao  6 , Luhua Wang  7 , Jie He  6
Affiliations
Clinical Trial

Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non-Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy: The Phase 3 PORT-C Randomized Clinical Trial

Zhouguang Hui et al. JAMA Oncol. .

Abstract

Importance: The role of postoperative radiotherapy (PORT) has not been well defined in resected pIIIA-N2 non-small cell lung cancer (NSCLC).

Objective: To evaluate the effect of PORT using modern techniques on survival and safety in patients with pIIIA-N2 NSCLC after complete resection and adjuvant chemotherapy.

Design, setting, and participants: The PORT-C randomized clinical trial was conducted in 394 patients with pIIIA-N2 NSCLC treated with complete resection and 4 cycles of platinum-based chemotherapy between January 2009 and December 2017. Data were analyzed between March 2019 and December 2020.

Interventions: Patients were randomized equally into the PORT arm (n = 202) or the observation arm (n = 192). The total dose of PORT was 50 Gy.

Main outcomes and measures: The primary end point was disease-free survival (DFS). Secondary end points included overall survival (OS), locoregional recurrence-free survival (LRFS), distant metastasis-free survival, and toxic effects.

Results: In total, 394 patients were enrolled and 364 were eligible, with a median (range) age of 55 (25-70) years. There were 202 (55.5%) male and 162 (44.5%) female patients. The median follow-up was 46.0 (95% CI, 41.9-51.4) months, and 230 DFS events were reported. There were 184 patients in the PORT arm and 180 patients in the observation arm. The 3-year DFS rates were 40.5% with PORT vs 32.7% with observation (median, 22.1 vs 18.6 months), and the difference in DFS was not statistically significant without adjustment (hazard ratio [HR], 0.84; 95% CI, 0.65-1.09; P = .20), though it was significant with preplanned yet exploratory analysis (stratified analysis by the number of detected lymph nodes and positive lymph nodes, HR, 0.75; log-rank P = .04). The 3-year OS rates were 78.3% vs 82.8% (HR, 1.02; P = .93), and LRFS was 66.5% vs 59.7% (HR, 0.71; 95% CI, 0.51-0.97; P = .03), respectively. For 310 per-protocol patients (140 with PORT and 170 with observation), PORT significantly improved DFS (42.8% vs 30.6%; HR, 0.75; 95% CI, 0.57-1.00; P = .05) but not OS (HR, 0.83; 95% CI, 0.53-1.30; P = .41). The 3-year local recurrence only rates were 9.5% and 18.3% in the 2 arms, respectively (Fine-Gray HR, 0.55; Gray test P = .04). No radiotherapy-related grade 4 or 5 adverse event was observed.

Conclusions and relevance: In this phase 3 randomized clinical trial of patients with pIIIA-N2 NSCLC after complete resection and adjuvant chemotherapy, PORT did not improve DFS. Further studies exploring patients who might best benefit from PORT are needed.

Trial registration: ClinicalTrials.gov Identifier: NCT00880971.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Hu reported receiving grants from the National Institutes of Health and RTOG Foundation and personal fees from Merck & Co outside the submitted work. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Participant Flow in the Randomized Clinical Trial
PORT indicates postoperative radiotherapy.
Figure 2.
Figure 2.. Kaplan-Meier Curves by Arm for Survivals Using Modified Intent-to-Treat (mITT) and Per-Protocol Populations
A, Disease-free survival (DFS) of mITT analysis; B, Overall survival (OS) of mITT analysis; C, DFS of per-protocol analysis; D, OS of per-protocol analysis. PORT indicates postoperative radiotherapy.
Figure 3.
Figure 3.. Failure Pattern, Modified Intent-to-Treat Population
DM indicates distant metastasis; LR, locoregional recurrence; PORT, postoperative radiotherapy.
See this image and copyright information in PMC

References

    1. PORT Meta-analysis Trialists Group . Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. Lancet. 1998;352(9124):257-263. doi:10.1016/S0140-6736(98)06341-7 - DOI - PubMed
    1. Lally BE, Zelterman D, Colasanto JM, Haffty BG, Detterbeck FC, Wilson LD. Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the Surveillance, Epidemiology, and End Results database. J Clin Oncol. 2006;24(19):2998-3006. doi:10.1200/JCO.2005.04.6110 - DOI - PubMed
    1. Dai H, Hui Z, Ji W, et al. . Postoperative radiotherapy for resected pathological stage IIIA-N2 non-small cell lung cancer: a retrospective study of 221 cases from a single institution. Oncologist. 2011;16(5):641-650. doi:10.1634/theoncologist.2010-0343 - DOI - PMC - PubMed
    1. Patel SH, Ma Y, Wernicke AG, Nori D, Chao KS, Parashar B. Evidence supporting contemporary post-operative radiation therapy (PORT) using linear accelerators in N2 lung cancer. Lung Cancer. 2014;84(2):156-160. doi:10.1016/j.lungcan.2014.02.016 - DOI - PubMed
    1. Douillard JY, Rosell R, De Lena M, et al. . Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006;7(9):719-727. doi:10.1016/S1470-2045(06)70804-X - DOI - PubMed

Publication types

Associated data